Zobrazeno 1 - 10
of 2 204
pro vyhledávání: '"obinutuzumab"'
Autor:
Wenxiu Shu, Qianqian Yang, Jing Le, Qianqian Cai, Hui Dai, Liufei Luo, Jiaqi Tong, Yanping Song, Bingrong Chen, Dengbing Chen, Dian Jin
Publikováno v:
Virology Journal, Vol 21, Iss 1, Pp 1-8 (2024)
Abstract Background Patients treated with anti-CD20 monoclonal antibodies could have a higher risk of adverse outcomes of coronavirus disease 2019 (COVID-19). The novel anti-CD20 monoclonal antibody obinutuzumab has shown greater B-cell depletion and
Externí odkaz:
https://doaj.org/article/44485df217bf44e9bec41ee461d19fe7
Publikováno v:
Linchuang shenzangbing zazhi, Vol 24, Iss 7, Pp 572-578 (2024)
Objective To explore the efficacy and safety of obinutuzumab (OBZ) for phospholipase A2 receptor（PLA2R）-associated membranous nephropathy (MN) with an intermediate-to-high risk of progression. MethodsFrom January 2022 to November 2022, ten patien
Externí odkaz:
https://doaj.org/article/79ad0a1fc0ce4b0b937bdb5a581e34e4
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionSystemic lupus erythematosus (SLE) is a complex autoimmune disease, and despite the availability of multiple treatments, striking a balance between long-term efficacy and side effects remains a major clinical challenge. B-cell–directed
Externí odkaz:
https://doaj.org/article/003a74e0ce6044b980070159225d1eef
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectiveTo retrospectively analyze the characteristics of newly diagnosed marginal zone lymphoma (MZL) patients, evaluate the efficacy of different treatment regimens, and explore prognostic factors in the era of immunotherapy.MethodsWe reviewed the
Externí odkaz:
https://doaj.org/article/9844375fc532470081e6696a09df4890
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 157-161 (2024)
Abstract Thrombocytopenia has been reported more frequently with obinutuzumab in clinical trials where it was directly compared with rituximab. However, more significant than the frequency, a unique form of severe thrombocytopenia manifesting very ea
Externí odkaz:
https://doaj.org/article/cc11b12b0ca848ffbba6b4296c88fcb0
Publikováno v:
Turkish Journal of Hematology, Vol 41, Iss 3, Pp 207-208 (2024)
Externí odkaz:
https://doaj.org/article/af2c0f98e6cd4929be23d6800c6cf570
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ashwath Gurumurthi, Collin K. Chin, Lei Feng, Nathan H. Fowler, Paolo Strati, Fredrick B. Hagemeister, Luis E. Fayad, Jason R. Westin, Chizobam Obi, Janine Arafat, Ranjit Nair, Raphael E. Steiner, Sattva S. Neelapu, Christopher R. Flowers, Loretta J. Nastoupil
Publikováno v:
EClinicalMedicine, Vol 74, Iss , Pp 102747- (2024)
Summary: Background: Rituximab and lenalidomide is a preferred option for relapsed indolent B cell non-Hodgkin lymphoma. Obinutuzumab may be a superior combination partner with lenalidomide given enhanced antibody dependent cellular cytotoxicity and
Externí odkaz:
https://doaj.org/article/ce025c6f41e44776b07e12e8ef403353
Autor:
Yuxin Lin, Quan Han, Liangliang Chen, Yaomin Wang, Pingping Ren, Guangjun Liu, Lan Lan, Xin Lei, Jianghua Chen, Fei Han
Publikováno v:
Kidney Medicine, Vol 6, Iss 8, Pp 100853- (2024)
Rationale & Objective: Membranous nephropathy (MN), recognized as an autoimmune kidney disease, responds well to anti-CD20 monoclonal antibodies. Obinutuzumab, a type Ⅱ humanized anti-CD20 and immunoglobulin G1 Fc-optimized monoclonal antibody, whe
Externí odkaz:
https://doaj.org/article/18d2e935fb924c73b8a07176f7d8b6e0
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundMinimal change disease (MCD) is a common cause of adult nephrotic syndrome. Most adults with MCD achieve complete remission (CR) after initial steroid therapy. However, approximately 30% of adults who respond to steroids experience frequent
Externí odkaz:
https://doaj.org/article/975fc8cfae8e47769ff62a5f724402f7